Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial.

MLA

Dimopoulos, Meletios A., et al. “Elotuzumab plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-up and Analysis of Relative Progression-Free Survival from the Randomized ELOQUENT-2 Trial.” Cancer (0008543X), vol. 124, no. 20, Oct. 2018, pp. 4032–43. EBSCOhost, https://doi.org/10.1002/cncr.31680.

APA

Dimopoulos, M. A., Lonial, S., Betts, K. A., Chen, C., Zichlin, M. L., Brun, A., Signorovitch, J. E., Makenbaeva, D., Mekan, S., Sy, O., Weisel, K., & Richardson, P. G. (2018). Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer (0008543X), 124(20), 4032–4043. https://doi.org/10.1002/cncr.31680

Chicago

Dimopoulos, Meletios A., Sagar Lonial, Keith A. Betts, Clara Chen, Miriam L. Zichlin, Alexander Brun, James E. Signorovitch, et al. 2018. “Elotuzumab plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-up and Analysis of Relative Progression-Free Survival from the Randomized ELOQUENT-2 Trial.” Cancer (0008543X) 124 (20): 4032–43. doi:10.1002/cncr.31680.